- Home
- CUBE vs ROIV Comparison
CUBE vs ROIV Comparison
Compare CUBE & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBE
- ROIV
- Stock Information
- Founded
- CUBE 2004
- ROIV 2014
- Country
- CUBE United States
- ROIV United Kingdom
- Employees
- CUBE N/A
- ROIV N/A
- Industry
- CUBE Real Estate Investment Trusts
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CUBE Real Estate
- ROIV Health Care
- Exchange
- CUBE Nasdaq
- ROIV Nasdaq
- Market Cap
- CUBE 9.7B
- ROIV 8.4B
- IPO Year
- CUBE 2004
- ROIV N/A
- Fundamental
- Price
- CUBE $41.29
- ROIV $10.87
- Analyst Decision
- CUBE Buy
- ROIV Buy
- Analyst Count
- CUBE 14
- ROIV 4
- Target Price
- CUBE $48.14
- ROIV $17.50
- AVG Volume (30 Days)
- CUBE 2.0M
- ROIV 5.2M
- Earning Date
- CUBE 05-01-2025
- ROIV 05-29-2025
- Dividend Yield
- CUBE 5.04%
- ROIV N/A
- EPS Growth
- CUBE N/A
- ROIV N/A
- EPS
- CUBE 1.69
- ROIV N/A
- Revenue
- CUBE $1,079,894,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CUBE $1.99
- ROIV N/A
- Revenue Next Year
- CUBE $3.76
- ROIV N/A
- P/E Ratio
- CUBE $24.43
- ROIV N/A
- Revenue Growth
- CUBE 1.89
- ROIV 140.04
- 52 Week Low
- CUBE $34.24
- ROIV $8.73
- 52 Week High
- CUBE $55.14
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CUBE 47.34
- ROIV 51.00
- Support Level
- CUBE $40.68
- ROIV $10.58
- Resistance Level
- CUBE $43.91
- ROIV $11.07
- Average True Range (ATR)
- CUBE 0.85
- ROIV 0.30
- MACD
- CUBE -0.17
- ROIV -0.04
- Stochastic Oscillator
- CUBE 18.89
- ROIV 30.21
About CUBE CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.